机构:[1]Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai 054000 Hebei, PR China[2]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000 Hebei, PR China临床科室胸心外科(胸外科 心脏血管外科)河北医科大学第四医院[3]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000 Hebei, PR China河北医科大学第四医院头颈放疗病区临床科室[4]Department of Surgical Oncology, Handan Central Hospital, Handan 056000 Hebei, PR China[5]School of Clinical Sciences, Hebei Medical University, Shijiazhuang 050000 Hebei, PR China
Medical Science Research Project of Hebei (No. 20230792) and the S&T Program of Hebei (No.H2023206301) and the Government funded the Clinical Medicine Excellent Talents Training Project of Hebei (No: ZF2024113).
第一作者机构:[1]Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai 054000 Hebei, PR China
共同第一作者:
通讯作者:
通讯机构:[3]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000 Hebei, PR China
推荐引用方式(GB/T 7714):
Wang Haijun,Liu Changjiang,Jiang Chao,et al.GRHL3 drives radiotherapy resistance and blocks the anti-tumor response of NK and CD4+ T cells in lung squamous cell carcinoma via RNF2[J].Biochemical Pharmacology.2025,233:116784.doi:10.1016/j.bcp.2025.116784.
APA:
Wang Haijun,Liu Changjiang,Jiang Chao,Zhang Yunjie,Zhao Xin...&Yang Jie.(2025).GRHL3 drives radiotherapy resistance and blocks the anti-tumor response of NK and CD4+ T cells in lung squamous cell carcinoma via RNF2.Biochemical Pharmacology,233,
MLA:
Wang Haijun,et al."GRHL3 drives radiotherapy resistance and blocks the anti-tumor response of NK and CD4+ T cells in lung squamous cell carcinoma via RNF2".Biochemical Pharmacology 233.(2025):116784